IPA250117P7500
- 0.00
- 0.000.00%
ImmunoPrecise Antibodies Newsroom
Further Upside For ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Shares Could Introduce Price Risks After 44% Bounce
Express News | Immunoprecise Antibodies Ltd - Kristin Taylor Resigns as CFO of Immunoprecise Antibodies
IPA Announces Resignation of Chief Financial Officer
Express News | Ipa Announces Resignation of Chief Financial Officer
ImmunoPrecise Antibodies CEO Jennifer Bath And BioStrand Co-Founders Dirk Van Hyfte And Ingrid Brands Collectively Acquired A Total Of 763,120 Shares Of IPA On The Open Market For An Aggregate Amount Of $306,000
ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence With Insider Share Purchases
IPA to Present at The Microcap Conference 2025
Benchmark Co. Maintains ImmunoPrecise Antibodies(IPA.US) With Buy Rating, Maintains Target Price $3
Analysts Offer Insights on Healthcare Companies: ImmunoPrecise Antibodies (IPA), Neurocrine (NBIX) and Becton Dickinson (BDX)
ImmunoPrecise Antibodies Is Maintained at Buy by HC Wainwright & Co.
ImmunoPrecise Antibodies Analyst Ratings
Express News | Immunoprecise Antibodies Ltd. : H.c. Wainwright Cuts Target Price to $7 From $9
Earnings Call Summary | ImmunoPrecise Antibodies(IPA.US) Q2 2025 Earnings Conference
ImmunoPrecise Antibodies Ltd. (IPA) Q2 2025 Earnings Call Transcript
ImmunoPrecise Antibodies Reports Q2 Results and Strategic Advances in AI-Driven Drug Discovery
ImmunoPrecise Antibodies Expands With Strategic Growth in Biologics and CRO Services
ImmunoPrecise Antibodies | 20-F/A: Registration statement / Annual report / Transition report (Amendment)
Express News | Immunoprecise Antibodies Q2 Net Income CAD -2.6 Million
ImmunoPrecise Antibodies 2Q Loss/Shr C$0.09 >IPA
ImmunoPrecise Antibodies 2Q Rev C$6.13M >IPA